Five-year efficacy and safety of tafasitamab in patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Final results from the phase II L-MIND study Meeting Abstract
| Authors: | Duell, J.; Abrisqueta, P.; Andre, M.; Augustin, M.; Gaidano, G.; Barca, E. G.; Jurczak, W.; Kalakonda, N.; Liberati, A. M.; Maddocks, K. J.; Menne, T.; Nagy, Z.; Tournilhac, O.; Bakuli, A.; Amin, A.; Gurbanov, K.; Salles, G. |
| Abstract Title: | Five-year efficacy and safety of tafasitamab in patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Final results from the phase II L-MIND study |
| Meeting Title: | 11th Annual Meeting of the Society of Hematologic Oncology (SOHO 2023): Progress in Personalized Therapy |
| Keywords: | lenalidomide; immunotherapy; diffuse large b-cell lymphoma (dlbcl); tafasitamab; l-mind |
| Journal Title: | Clinical Lymphoma, Myeloma and Leukemia |
| Volume: | 23 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2023 Sep 6-9 |
| Meeting Location: | Houston, TX |
| ISSN: | 2152-2650 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2023-09-01 |
| Start Page: | S433 |
| End Page: | S434 |
| Language: | English |
| ACCESSION: | WOS:001062479600455 |
| PROVIDER: | wos |
| DOI: | 10.1016/S2152-2650(23)01322-8 |
| Notes: | Meeting Abstract: ABCL-450 -- Source: Wos |
